Armored CAR T Cells in Multiple Myeloma
Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.
Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of armored chimeric antigen receptor (CAR) T cells in multiple myeloma.
At Memorial Sloan Kettering, armored CAR T cells are used to encode at least 2 genes, 1 being the CAR itself and the second being a gene that gives T cells an advantage. According to Smith, it could be a proinflammatory cytokine that make T cells better killers. It could also be a ligand that is expressed on the surface and interacts with other cells in the tumor microenvironment.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
